<DOC>
	<DOCNO>NCT00737568</DOCNO>
	<brief_summary>The aim therapy treatment chronic hepatitis B virus ( HBV ) maintain suppression viral replication prevent emergence complication , require long-term therapy . Durable suppression viral replication achieve treatment chronic viral disease prevent emergence drug-resistant mutation . The clinical guideline management lamivudine resistant patient variable . Some recommend switch another agent without cross-resistance , others recommend add another agent without cross-resistance . Limited clinical data exists demonstrate whether tenofovir disoproxil fumarate ( tenofovir DF ; TDF ) effective monotherapy lamivudine resistant patient use part combination therapy regimen . This study design evaluate effectiveness , safety , tolerability tenofovir DF monotherapy versus emtricitabine ( FTC ) /tenofovir DF combination therapy participant chronic HBV lamivudine resistance ( presence rtM204I/V mutation without rtL180M mutation ) 240-week period . Participants study must receive lamivudine treatment time enrollment .</brief_summary>
	<brief_title>Tenofovir Disoproxil Fumarate ( Tenofovir DF ) Versus Emtricitabine/Tenofovir DF Subjects Resistant Lamivudine</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Chronic HBV infection , define positive serum HBsAg least 6 month 18 75 year age , inclusive HBV DNA ≥ 10^3 IU/mL Receiving treatment lamivudine confirmation HBV reverse transcriptase mutation ( ) know confer resistance lamivudine ( rtM204I/V without rtL180M ) central laboratory assessment prior randomization ; adefovir dipivoxil treatment ≤ 48 week time screen ( inclusive combination adefovir dipivoxil + lamivudine entry ) allow Willing able provide write informed consent Negative serum pregnancy test ( female childbearing potential ) Calculated creatinine clearance ≥ 50 mL/min Hemoglobin ≥ 10 g/dL Neutrophils ≥ 1000 /mm^3 No prior oral HBV therapy approve nucleotide and/or nucleoside therapy investigational agent HBV infection lamivudine adefovir dipivoxil Exclusion Criteria Pregnant woman , woman breast feed believe may wish become pregnant course study Males females reproductive potential willing use effective method contraception study Alanine aminotransferase ( ALT ) ≥ 10 × upper limit normal range ( ULN ) Decompensated liver disease Interferon pegylated interferon therapy within 6 month screen visit Alpha fetoprotein &gt; 50 ng/mL Evidence hepatocellular carcinoma Coinfection hepatitis C virus , HIV , hepatitis D virus Significant renal , cardiovascular , pulmonary , neurological disease Received solid organ bone marrow transplantation Receiving therapy immunomodulators ( eg , corticosteroid , etc . ) , investigational agent , nephrotoxic agent , agent susceptible modify renal excretion Proximal tubulopathy Known hypersensitivity study drug , metabolite formulation excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Tenofovir DF</keyword>
	<keyword>Emtricitabine</keyword>
	<keyword>Chronic hepatitis B</keyword>
	<keyword>Combination therapy</keyword>
</DOC>